News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Mesoblast Limited Interview With MD Silviu Itescu On Angioblast - Progression of Four Phase 2 Trial Applications
September 1, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Melbourne, Sep 1, 2009 (ABN Newswire) - Mesoblast Limited (ASX:MSB)(PINK:MBLTY) is pleased to provide an interview with MD Silviu Itescu on its United States-based associate company Angioblast Systems Inc.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Asia
Australia
MORE ON THIS TOPIC
Insights
From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM
January 22, 2026
·
1 min read
·
Jennifer Smith-Parker
Insights
The New Gold Rush in Brain Science
January 22, 2026
·
5 min read
·
Jennifer Smith-Parker
Collaboration
GSK Joins Growing PD-1 SubQ Push With Alteogen Alliance Worth up to $285M+
January 21, 2026
·
1 min read
·
Tristan Manalac
Podcast
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
January 21, 2026
·
1 min read
·
Heather McKenzie
